title: P53 codon 72 polymorphism in Taiwanese breast cancer patients.
abstract: There are clear discrepancies between ethnicity and geographic area regarding the peak age incidence and mortality of breast cancer. Underlying variances include genetic, environmental, and socioeconomic factors. The wild-type p53 codon has two common polymorphic variants from a single-base-pair substitution at codon 72, where either C-C-C encodes proline (p53-p72) or C-G-C encodes arginine (p53-R72). We aim to study the p53 codon 72 genotypes of patients with breast cancer in Taiwan and make a comparison with the published data to ascertain whether any difference exists between Taiwanese and Western patients with breast cancer. We also evaluated the effect of the p53 codon 72 polymorphism on clinicopathologic features. We examined blood from 170 Taiwanese women with breast cancer with polymerase chain reaction-restriction fragment length polymorphism for the genotypes of p53 codon 72. For the p53 codon 72 polymorphism, there were 31 p53-P/P72 (18.2%), 93 p53-R/P72 (54.7%), and 46 p53-R/R72 (27.1%) with the allele frequencies 0.54 for the p53-R72 and 0.46 for p53-P72, respectively. Our results indicate that there was more p53-P72 (40.6% in Asians vs. 26.4% in Caucasians) and twice the incidence of p53-P/P72 homozygotes (18% in Asians vs. 8% in Caucasians) among the Asian population. Patients with the p53-R/R72 variant were more likely to have a t1 tumor size status (55.2%) compared with patients with the P53-P/R72 (30.9%) or P53-P/P72 variant (36%). Our results support the hypothesis that genetic factors may contribute to the difference between Taiwanese or Asian breast cancer and Western breast cancer patient populations.
authors: Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
authors: Fang-Ming
authors: FM
authors: Chen
authors: Fu
authors: F
authors: Ou-Yang
authors: Sheau-Fang
authors: SF
authors: Yang
authors: Eing-Mei
authors: EM
authors: Tsai
authors: Ming-Feng
authors: MF
authors: Hou
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000235:genetics* / Q000473:pathology; D003062:Codon; D005260:Female; D005787:Gene Frequency; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors; D017422:Sequence Analysis, DNA; D013624:Taiwan; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D003062:Codon; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53
references: Cancer Res. 2007 Oct 1;67(19):9584-90
references: 17909070
references: Clin Cancer Res. 2005 Oct 15;11(20):7328-33
references: 16243804
references: Cancer Lett. 2004 Jul 16;210(2):151-7
references: 15183530
references: Hum Mutat. 2000;15(1):105-13
references: 10612830
references: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references: 20610543
references: Clin Cancer Res. 2005 Jul 15;11(14):5098-103
references: 16033823
references: Cancer Lett. 2005 May 10;222(1):57-65
references: 15837541
references: Nat Rev Cancer. 2009 Feb;9(2):95-107
references: 19165225
references: Br J Cancer. 2005 Mar 28;92(6):1144-8
references: 15756275
references: J Biol Chem. 1998 Jan 2;273(1):1-4
references: 9417035
references: J Natl Cancer Inst. 2002 May 1;94(9):681-90
references: 11983757
references: Cancer Lett. 2002 Sep 26;183(2):123-30
references: 12065086
references: J Biol Chem. 2011 May 20;286(20):18251-60
references: 21454683
references: Clin Cancer Res. 1999 Jan;5(1):129-34
references: 9918210
references: Nat Genet. 2000 May;25(1):47-54
references: 10802655
references: Hum Genet. 2009 Jun;125(5-6):633-8
references: 19357867
references: Kaohsiung J Med Sci. 2001 Feb;17(2):64-76
references: 11416960
references: Cell. 1997 Feb 7;88(3):323-31
references: 9039259
references: Clin Breast Cancer. 2005 Dec;6(5):391-401
references: 16381622
references: Breast Cancer. 2003;10(4):307-11
references: 14634508
references: Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1684-8
references: 12496062
references: J Biomed Sci. 2003 Jul-Aug;10(4):430-5
references: 12824702
references: Cancer Lett. 2004 Jul 16;210(2):197-203
references: 15183535
references: Mol Cell Biol. 1999 Feb;19(2):1092-100
references: 9891044
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Pharmacogenet Genomics. 2006 May;16(5):347-51
references: 16609366
references: Mol Cell Biol. 1987 Feb;7(2):961-3
references: 3547088
references: Clin Cancer Res. 2003 Oct 15;9(13):4860-4
references: 14581358
references: Breast Cancer Res Treat. 2010 Apr;120(2):509-17
references: 19629678
references: Carcinogenesis. 2006 Apr;27(4):766-71
references: 16314399
references: Hum Hered. 1994 Sep-Oct;44(5):266-70
references: 7927355
references: Int J Cancer. 2003 Jan 20;103(3):431-3
references: 12471629
references: Oncogene. 2004 Apr 22;23(19):3328-37
references: 15077186
references: Clin Cancer Res. 2005 Jun 15;11(12):4348-56
references: 15958617
references: Cancer Res. 1994 Sep 15;54(18):4855-78
references: 8069852
references: Cancer Lett. 2004 Apr 15;207(1):59-67
references: 15050734
references: Adv Cancer Res. 2000;77:81-137
references: 10549356
references: Nature. 1998 May 21;393(6682):229-34
references: 9607760
references: Mol Cell Biol Res Commun. 2000 Jun;3(6):389-92
references: 11032762